Ulcerative Colitis Clinical Trials

24 trials recruiting in Canada.

Digestive Health

Recruiting Drug Device Behavioral Older adults Healthy volunteers

17 trials

Testing LY4268989 against a placebo for ulcerative colitis (UC)

Explore this study →

There are 3 groups in this study. Groups A and B receive LY4268989. Group C, the placebo group, receives Placebo.

Sites in Greater Sudbury, Halifax and 1 more city

Phase 2
3 groups
Sites in Greater Sudbury, Halifax and 1 more city
Recruiting

Official title: LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC) · Eli Lilly and Company

Comparing LY4268989 with Mirikizumab for ulcerative colitis

Explore this study →

There are 2 groups in this study. Group A receives LY4268989 and Mirikizumab. Group B receives Mirikizumab and LY4268989 Placebo.

Sites in London, Hamilton and 2 more cities

Phase 2
2 groups
Sites in Hamilton, London and 2 more cities
Recruiting

Official title: LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Ulcerative Colitis · Eli Lilly and Company

Comparing Tirzepatide with Mirikizumab for ulcerative colitis

Explore this study →

There are 2 groups in this study. Group A receives Mirikizumab and Tirzepatide. Group B receives Mirikizumab and Placebo.

Sites in London, Vancouver and 2 more cities

Phase 3
2 groups
Sites in London, Montreal and 2 more cities
Recruiting

Official title: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis · Eli Lilly and Company

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for ulcerative colitis.

Testing XmAb942 against a placebo for ulcerative colitis (UC)

Explore this study →

There are 6 groups in this study. Groups A, C and E, the comparison group, receive XmAb942. Groups B, D and F, the placebo group, receive Placebo.

Sites in London, Montreal and 2 more cities

Phase 1
6 groups
Sites in London, Montreal and 2 more cities
Recruiting

Official title: Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Ulcerative Colitis (UC) · Xencor, Inc.

Testing SPY001 against a placebo for ulcerative colitis

Explore this study →

There are 13 groups in this study. Groups A, D and E receive SPY001. Groups B, F and G receive SPY002. Groups C, H and I receive SPY003. …and 4 more groups.

Sites in London, Montreal and 3 more cities

Phase 2
13 groups
Sites in London, Toronto and 3 more cities
Recruiting

Official title: A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis · Spyre Therapeutics, Inc.

Comparing 5 approaches for ulcerative colitis

Explore this study →

There are 5 groups in this study. Groups A, B, C and D receive RO7837195. Group E receives RO7837195 and RO7837195 Matched Placebo.

Sites in Montreal and London

Phase 2
5 groups
Sites in London and Montreal
Recruiting

Official title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis · Genentech, Inc.

Testing Duvakitug against a placebo for ulcerative colitis

Explore this study →

There are 3 groups in this study. Groups A and B receive Duvakitug. Group C, the placebo group, receives Placebo.

Sites in Hamilton, Oakville and 1 more city

Phase 3
3 groups
Sites in Hamilton, Oakville and 1 more city
Recruiting

Official title: An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis · Sanofi

Testing PALI-2108 against a placebo for ulcerative colitis (UC)

Explore this study →

There are 3 groups in this study. Groups A and B receive PALI-2108. Group C, the placebo group, receives Placebo.

Sites in Montreal, Calgary and 4 more cities

Phase 2
3 groups
Sites in Calgary, Edmonton and 4 more cities
Recruiting

Official title: A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC) · Palisade Bio

Testing Duvakitug against a placebo for ulcerative colitis

Explore this study →

There are 4 groups in this study. Groups A, B and C receive Duvakitug. Group D, the placebo group, receives Placebo.

Sites in Edmonton, Hamilton and 3 more cities

Phase 3
4 groups
Sites in Toronto, Edmonton and 3 more cities
Recruiting

Official title: A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis · Sanofi

Testing Vancomycin (blinded) with Vancomycin (open-label extension) against a placebo for ulcerative colitis (UC)

Explore this study →

There are 2 groups in this study. Group A, the placebo group, receives one or more of: Placebo (blinded) and Vancomycin (open-label extension). Group B receives one or more of: Vancomycin (blinded) and Vancomycin (open-label extension).

One site, in Hamilton

Phase 2
2 groups
One site, in Hamilton
Recruiting

Official title: Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

Ulcerative Colitis (UC) · McMaster University

Comparing 4 approaches for ulcerative colitis

Explore this study →

There are 4 groups in this study. Group A receives Eltrekibart and Placebo, together with one or more of: Mirikizumab. Group B receives Mirikizumab and Placebo. Group C receives Eltrekibart and Mirikizumab. …and 1 more groups.

Sites in London and Montreal

Phase 2
4 groups
Sites in London and Montreal
Recruiting

Official title: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis · Eli Lilly and Company

Testing Vedolizumab with Tofacitinib for ulcerative colitis

Explore this study →

Everyone in this study receives Vedolizumab and Tofacitinib.

Sites in Barrie, London and 7 more cities

Phase 4
1 group
Sites in Barrie, London and 6 more cities
Recruiting

Official title: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Ulcerative Colitis · Takeda

Comparing 3 approaches for ulcerative colitis (UC)

Explore this study →

There are 3 groups in this study. Groups A, B and C receive OD-07656, together with one or more of: Vedolizumab.

2 sites in Montreal

Phase 2
3 groups
2 sites in Montreal
Recruiting

Official title: Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC) · Odyssey Therapeutics

Testing Afimkibart against a placebo for moderately to severely active ulcerative colitis

Explore this study →

There are 2 groups in this study. Group A receives Afimkibart. Group B, the placebo group, receives Placebo.

Sites in London, Barrie and 3 more cities

Phase 3
2 groups
Sites in Barrie, Brampton and 3 more cities
Recruiting

Official title: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis · Hoffmann-La Roche

Testing Tilpisertib Fosmecarbil against a placebo for ulcerative colitis

Explore this study →

There are 4 groups in this study. Groups A, B and C receive Tilpisertib Fosmecarbil. Group D, the placebo group, receives Tilpisertib Fosmecarbil and Placebo.

Sites in Toronto, London and 1 more city

Phase 2
4 groups
Sites in London, Toronto and 1 more city
Recruiting

Official title: Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis · Gilead Sciences

Comparing 7 approaches for ulcerative colitis

Explore this study →

There are 7 groups in this study. Groups A, B, C, D, E and F receive Vedolizumab IV. Group G receives No Intervention.

Sites in Edmonton, London and 2 more cities

Phase 3
7 groups
Sites in Edmonton, Vancouver and 2 more cities
Recruiting

Official title: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Ulcerative Colitis · Takeda

Testing Lyophilized fecal microbiota against a placebo for ulcerative colitis

Explore this study →

There are 4 groups in this study. Groups A and C receive Lyophilized fecal microbiota (LFMT). Groups B and D, the placebo group, receive Placebo.

One site, in Edmonton

Phase 2
4 groups
One site, in Edmonton
Recruiting

Official title: LFMT vs Placebo in New Biologic Start for Ulcerative Colitis

Ulcerative Colitis · University of Alberta

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Ulcerative Colitis trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.